Should We Use PPAR Agonists to Reduce Cardiovascular Risk?

Figure 1

Approximate expected cardiovascular (CVD) risk reduction from percent changes in LDL and HDL versus observed percent reduction in coronary heart disease (CHD) or CVD. Above the slope = 1 line, CVD risk reduction was worse than expected based on lipid changes; below the slope = 1 line, CVD risk reduction was greater than expected based on the lipid changes.